Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease

NCT02168842 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT02168842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02168842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease
Lead sponsor
University of Rochester
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2014
Completion date
November 30, 2018
Enrollment
336 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease